Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Governance at a Glance
Chair
Member
| Board Members | Audit | Compensation | Nominating and Corporate Governance | Science & Technology |
|---|---|---|---|---|
|
Steven Nichtberger, M.D. |
||||
|
Catherine Bollard, M.D. |
|
|
||
|
Scott Brun, M.D. |
|
|
|
|
|
Richard Henriques, M.B.A. |
|
|
||
|
Mark Simon, M.B.A. |
|
|
|
|
|
Shawn Tomasello, M.B.A. |
|
|